With new and emerging pandemics which can quickly cross borders, antibiotics that are no longer effective and environmental changes, infectious diseases pose a continual and rising threat to humankind. We are committed to serving the needs of both developed and developing countries, and as a result have a team dedicated to addressing pathogens of global concern.
Extra-intestinal pathogenic Escherichia coli (ExPEC) strains are an important cause of life-threatening bacterial illness such as sepsis in the elderly. We have launched a program in partnership with GlycoVaxyn of Switzerland to design and develop a vaccine aimed at protecting against the major ExPEC serotypes.
We are collaborating with international health organizations including the World Health Organization (WHO) and The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), and other key stakeholders, governments and public health authorities on the clinical testing, development, production and distribution of a monovalent vaccine regimen for the 2014 Ebola outbreak. The vaccine regimen, which was discovered in a collaborative research program with the NIH, includes a prime-boost combination of two components that are based on AdVac® technology from Janssen and the MVA-BN® technology from Bavarian Nordic, a biotechnology company based in Denmark. In addition we have a multivalent vaccine development program running concurrently to evaluate several strains of Ebola and Marburg.
The World Health Organization's (WHO) plan for a polio-free world depends on the availability of inactivated poliovirus vaccines (IPV). We are developing a PER.C6®-based IPV and are seeking to collaborate with other global health stakeholders.
Dengue, also known as breakbone fever, is a viral infection transmitted by mosquitoes and is endemic to almost all tropical and subtropical areas of the world. The disease causes flu-like symptoms, which in some cases can become life-threatening. Janssen joined with the Wellcome Trust, a global charitable foundation, and the University of Leuven in Belgium for the development of antiviral medicines to fight dengue. Read more about this collaboration.